Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Grieco

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 9, 2021
Lymphomatoid drug reaction developed after BNT162b2 (Comirnaty) COVID-19 vaccine manifesting as pityriasis lichenoides et varioliformis acuta-like eruptionA Sernicola, A Dybala, V Gomes, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 8, 2023
Telogen effluvium in SARS-CoV-2 infection: Histological aspectsS Michelini, G Caro, M Di Fraia, et al.
Frontiers in Pharmacology|December 12, 2025
Estrogen associations with human pregnancy related increases in cytochrome P450 3A activityMuluneh M Fashe, Jonghwa Lee, Joseph T Grieco, et al.
Clinical and Experimental Dermatology|July 26, 2021
Dupilumab in adolescents with moderate to severe atopic dermatitis: a 32-week real-world experience during the COVID-19 pandemicK Hansel, C Patruno, E Antonelli, et al.
Minerva Medica|April 27, 2001
[Importance of dermatologic screening within the frame work of a general cancer prevention program]V Lacava, N Salesi, L Ferrone, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 17, 2020
Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life studyC Patruno, M Napolitano, G Argenziano, et al.
The Journal of Dermatological Treatment|October 25, 2019
Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitisM C Fargnoli, M Esposito, S Ferrucci, et al.
The Journal of Dermatological Treatment|May 22, 2020
A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitisM C Fargnoli, M Esposito, S Ferrucci, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 9, 2021
Lymphomatoid drug reaction developed after BNT162b2 (Comirnaty) COVID-19 vaccine manifesting as pityriasis lichenoides et varioliformis acuta-like eruptionA Sernicola, A Dybala, V Gomes, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 8, 2023
Telogen effluvium in SARS-CoV-2 infection: Histological aspectsS Michelini, G Caro, M Di Fraia, et al.
Frontiers in Pharmacology|December 12, 2025
Estrogen associations with human pregnancy related increases in cytochrome P450 3A activityMuluneh M Fashe, Jonghwa Lee, Joseph T Grieco, et al.
Clinical and Experimental Dermatology|July 26, 2021
Dupilumab in adolescents with moderate to severe atopic dermatitis: a 32-week real-world experience during the COVID-19 pandemicK Hansel, C Patruno, E Antonelli, et al.
Minerva Medica|April 27, 2001
[Importance of dermatologic screening within the frame work of a general cancer prevention program]V Lacava, N Salesi, L Ferrone, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 17, 2020
Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life studyC Patruno, M Napolitano, G Argenziano, et al.
The Journal of Dermatological Treatment|October 25, 2019
Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitisM C Fargnoli, M Esposito, S Ferrucci, et al.
The Journal of Dermatological Treatment|May 22, 2020
A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitisM C Fargnoli, M Esposito, S Ferrucci, et al.
Pageof 3